Jamie B. Spangler

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.

The paper identifies a NRCAM proteoform with skipped microexons as a targetable surface antigen in pHGG and demonstrates its utility in immunotherapy.

The paper shows PAR induces a conformational switch in FUS, enabling sustained condensation through N-terminal PrLD interactions after PAR degradation.

This paper presents a nanovial-based platform for high-throughput functional screening of CAR T cell libraries, identifying CAR constructs with distinct secretion profiles over time.

This paper presents computational methods for designing GPCR-binding miniproteins and validates them through high-throughput screening, producing agonists and antagonists for multiple GPCRs.

This study identifies an IL-2 mutant that disrupts alternative signaling by blocking CD25-CCR7 complex formation while preserving canonical signaling.

The paper develops a computational model to analyze how bispecific antibodies interact with IL-6 and IL-8 receptors, showing how binding dynamics influence therapeutic efficacy.

This paper investigates how dynamic structural networks in IL-2 superkines affect receptor binding and signaling, showing that modulating core dynamics can improve immune cell selectivity.

The paper designs EndoTags to trigger endocytosis and degradation of target proteins, enabling tissue-specific targeting and therapeutic applications.